- Report
- October 2024
- 199 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 93 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 164 Pages
Global
From €4960EUR$5,450USD£4,252GBP
- Report
- April 2025
- 78 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2024
- 160 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- September 2024
- 80 Pages
Japan
From €3185EUR$3,500USD£2,731GBP
- Report
- March 2025
- 97 Pages
Global
From €3500EUR$4,120USD£3,106GBP
Beta Interferon is a type of biotechnology drug used to treat multiple sclerosis (MS). It is a synthetic form of a naturally occurring protein that helps to reduce inflammation and slow the progression of MS. Beta Interferon is administered through injections and is used to reduce the frequency of MS relapses. It is also used to reduce the severity of symptoms and slow the progression of disability.
Beta Interferon is one of the most widely used treatments for MS, and is often prescribed in combination with other therapies. It is also used to treat other neurological conditions, such as chronic inflammatory demyelinating polyneuropathy.
The Beta Interferon market is highly competitive, with several major players offering a range of products. Companies in the market include Biogen, Merck, Novartis, Sanofi, and Teva Pharmaceuticals. Show Less Read more